All In Biotech

Drug Trial Radar · NCT07776691

A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)

A Phase 3, Randomized, Open-label Study of Raludotatug Deruxtecan (MK-5909, R-DXd) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced Non-HRD-Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (ENGOT-ov102/MITO/GOG-3141/ REJOICE-Ovarian 04)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 802 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

802

Planned (sponsor's estimate)

Start

Sep 18, 2026

Primary completion

Mar 19, 2032

Study completion Oct 22, 2034

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Aug 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. Observation, which is watching to see if cancer grows or worsens. The study medicine, raludotatug deruxtecan- R-DXd, is a targeted therapy. The goal of this study is to learn if people who receive R-DXd maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.

Conditions

  • Ovarian Cancer
  • Ovarian Neoplasms
  • Peritoneal Cancer
  • Fallopian Tube Cancer

Interventions

  • R-DXdBiological

    R-DXd administered as an intravenously (IV) infusion

  • BevacizumabDrug

    Administered as an intravenously IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Up to approximately 4 years
  2. Overall Survival (OS)Time frame: Up to approximately 5.5 years

Locations

18 sites in 5 countries. Site status is shown where the registry gives one.

  • MedStar Washington Hospital Center ( Site 0026)

    Washington D.C., District of Columbia · Recruiting

  • Lahey Hospital & Medical Center ( Site 0031)

    Burlington, Massachusetts · Recruiting

  • Zangmeister Cancer Center ( Site 0043)

    Columbus, Ohio · Recruiting

  • Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8000)

    Eugene, Oregon · Recruiting

  • Alliance Cancer Specialists (ACS) ( Site 8008)

    Horsham, Pennsylvania · Recruiting

  • Texas Oncology - West Texas ( Site 8009)

    Amarillo, Texas · Recruiting

  • Texas Oncology - Central/South Texas ( Site 8002)

    Austin, Texas · Recruiting

  • Texas Oncology - DFW ( Site 8005)

    Fort Worth, Texas · Recruiting

  • Texas Oncology - The Woodlands ( Site 8003)

    The Woodlands, Texas · Recruiting

  • Texas Oncology - Northeast Texas ( Site 8004)

    Tyler, Texas · Recruiting

  • Northwest Cancer Specialists (Compass Oncology) ( Site 8007)

    Vancouver, Washington · Recruiting

  • Rambam Health Care Campus ( Site 1402)

    Haifa, Israel · Recruiting

  • Sourasky Medical Center ( Site 1403)

    Tel Aviv, Israel · Recruiting

  • Seoul National University Hospital ( Site 2301)

    Seoul, South Korea · Recruiting

  • Severance Hospital, Yonsei University Health System ( Site 2302)

    Seoul, South Korea · Recruiting

  • Samsung Medical Center ( Site 2303)

    Seoul, South Korea · Recruiting

  • National Cheng Kung University Hospital ( Site 2601)

    Tainan, Taiwan · Recruiting

  • Royal Lancaster Infirmary ( Site 2808)

    Lancaster, Lancashire, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.